P
Paul B. Chapman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 252
Citations - 38502
Paul B. Chapman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Melanoma & Vemurafenib. The author has an hindex of 67, co-authored 242 publications receiving 34848 citations. Previous affiliations of Paul B. Chapman include Cornell University & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T. Flaherty,Igor Puzanov,Kevin B. Kim,Antoni Ribas,Grant A. McArthur,Jeffrey A. Sosman,Peter J. O'Dwyer,Richard J. Lee,Joseph F. Grippo,K. B. Nolop,Paul B. Chapman +10 more
TL;DR: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
Journal ArticleDOI
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Héctor Peinado,Maša Alečković,Simon Lavotshkin,Irina Matei,Bruno Costa-Silva,Gema Moreno-Bueno,Marta Hergueta-Redondo,Caitlin Williams,Guillermo García-Santos,Cyrus M. Ghajar,Ayuko Nitadori-Hoshino,Caitlin Hoffman,Karen Badal,Benjamin A. Garcia,Margaret K. Callahan,Jianda Yuan,Vilma R. Martins,Johan Skog,Rosandra N. Kaplan,Mary S. Brady,Jedd D. Wolchok,Jedd D. Wolchok,Paul B. Chapman,Paul B. Chapman,Yibin Kang,Yibin Kang,Jacqueline Bromberg,Jacqueline Bromberg,David Lyden +28 more
TL;DR: The data show that exosome production, transfer and education of bone marrow cells supports tumor growth and metastasis, has prognostic value and offers promise for new therapeutic directions in the metastatic process.
Journal ArticleDOI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild,Jean-Jacques Grob,Lev V. Demidov,Thomas Jouary,Ralf Gutzmer,Michael Millward,Piotr Rutkowski,Christian U. Blank,Wilson H. Miller,Eckhart Kaempgen,Salvador Martín-Algarra,Boguslawa Karaszewska,Cornelia Mauch,Vanna Chiarion-Sileni,Anne-Marie Martin,Suzanne Swann,Patricia Haney,Beloo Mirakhur,Mary E. Guckert,Vicki L. Goodman,Paul B. Chapman +20 more
TL;DR: Dabrafenib significantly improved progression-free survival compared with dacarbazine, and skin-related toxic effects, fever, fatigue, arthralgia, and headache were uncommon in both groups.
Journal ArticleDOI
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma
Gideon Bollag,Peter Hirth,James Tsai,Jiazhong Zhang,Prabha N. Ibrahim,Hanna Cho,Wayne Spevak,Chao Zhang,Ying Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Garson Tsang,Brian L. West,Ben Powell,Rafe Shellooe,Adhirai Marimuthu,Hoa Nguyen,Kam Y. J. Zhang,Dean R. Artis,Joseph Schlessinger,Fei Su,Brian Higgins,Raman Mahadevan Iyer,Kurt D'Andrea,Astrid Koehler,Michael Stumm,Paul S. Lin,Richard J. Lee,Joseph F. Grippo,Igor Puzanov,Kevin B. Kim,Antoni Ribas,Grant A. McArthur,Jeffrey A. Sosman,Paul B. Chapman,Keith T. Flaherty,Xiaowei Xu,Katherine L. Nathanson,K. B. Nolop +39 more
TL;DR: The structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity, and a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily are described, demonstrating that BRAF-mutant melanomas are highly dependent on B- RAF kinases activity.